Headquartered in Boulder, CO Fiscal year ends December NASDAQ: EWTX edgewisetx.com
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on novel, muscle-targeted therapeutics for cardiovascular diseases. Leveraging expertise in muscle biology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs including hypertrophic cardiomyopathy (HCM), heart failure with preserved ejection fraction (HFpEF), and other serious cardiovascular and cardiometabolic conditions. The company's lead program, EDG-7500, is a cardiac myosin inhibitor in Phase 2 development for HCM with Phase 3 initiation expected in Q4 2026. EDG-15400 is a novel oral selective cardiac sarcomere modulator being developed for heart failure. In July 2026, Edgewise completed the sale of its sevasemten program and muscular dystrophy business to Servier for $1.55 billion upfront and up to $1.1 billion in milestones, transitioning the company to a pure cardiovascular-focused organization. The company is pre-revenue and trades on the Nasdaq under the ticker EWTX. Updated
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on novel, muscle-targeted therapeutics for cardiovascular diseases.
The Wall Street consensus 12-month price target for EWTX is $52.62.
